At the time of writing this manuscript, there is an ongoing trial (NCT02890758) for different types of cancers, including MDS, where patients receive NK cells from HLA-mismatched donors either alone or in combination with IL-15 infusions. Here, IL15 is linked to myelodysplastic syndrome.